Clinical Trials Logo

Clinical Trial Summary

Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question arises whether colchicine, administered in a relatively low dose, could potentially have an effect the patients' clinical course by limiting the myocardial necrosis and pneumonia development in the context of COVID-19. If present, this effect would be attributed to its potential to inhibit inflammasome and (less probably) to the process of SARS-CoV-2 endocytosis in myocardial and endothelial respiratory cells.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04326790
Study type Interventional
Source National and Kapodistrian University of Athens
Contact
Status Terminated
Phase Phase 2
Start date April 3, 2020
Completion date April 27, 2020